Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the pharmacodynamic equivalence of triptorelin
pamoate (Pamorelin® LA 11.25 mg), applied either IM or SC, in terms of the area under the
curve [AUC1-85day] for serum testosterone in patients with advanced prostate cancer.